Accuracy Of Contrast Enhanced Mamography in Predicting Response of Breast Cancer Post Neoadjuvant Chemotherapy

Contrast Enhanced Mamography in Predicting Response of Breast Cancer Post Neoadjuvant Chemotherapy

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05141279

Enrollment

Registered

2021-12-02

Start date

2021-12-01

Completion date

2024-01-01

Last updated

2021-12-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer

Brief summary

The aim of this work to evaluate the accuracy of contrast enhanced spectral mamography in predicting the response to NAC and assessment of residual disease in breast cancer patients

Detailed description

This a prospective series ,will be performed for 50 patients diagnosed by biopsy as breast cancer who will be scheduled for surgery after completing the full coarse of neoadjuvant chemotherapy

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Inclusion criteria

* patient confirmed diagnosed by early breast cancer decided to received neoadjuvant treatment * locally advanced breast cancer * operable metastatic breast cancer

Exclusion criteria

* patient not candidate for NAC * contrast allergy * renal impairment * pregnancy

Design outcomes

Primary

Measure	Time frame
Accuracy of contrast enhanced spectral mamography in the predicting of pathological response to NAC and assessment residual disease in breast cancer patients	Basline

Secondary

Measure	Time frame
Assess best imaging modalities in pedict post neoadjuvant response	Baseline

Outcome results